Dr Shanade Dunn | Postdoctoral Fellow

This person is a member of Sanger Institute Alumni.

Dunn, Shanade

I am performing CRISPR-Cas9 genome-wide screening in cancer cells to identify genes that confer drug resistance and sensitivity. This project is carried out in collaboration with AstraZeneca, with the aim of using this information to develop novel anticancer therapies.


  • ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.

    Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S et al.

    Nature genetics 2020

Dunn, Shanade